Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
General16 hours agoAccused of Antisemitism: Herald Sun, Israel lobby v Dandenong Clr Rhonda Garad
-
Noosa News16 hours agoMitch Power Quick Shear event gets men talking about mental health
-
Noosa News18 hours agoRaising your voice | Noosa Today
-
Noosa News9 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs